Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Goya Wannamethee, A G Shaper, P H Whincup

Abstract
Objectives – To assess the relationship between haematocrit and risk of major ischaemic heart disease events.
Design – Prospective study of a cohort of men followed up for 9-5 years.
Setting – General practices in 24 towns in England, Wales, and Scotland (British Regional Heart Study).
Subjects – Altogether 7735 men aged 40–59 years at screening, who were selected at random from one general practice in each of 24 towns, were studied.
Main outcome measures – Fatal and non-fatal ischaemic heart disease events.
Results – Risk of major ischaemic heart disease events was significantly increased at haematocrit levels of ≥46.0%. Men with raised haematocrit (>46.0%) showed a 30% increase in relative risk (RR) of major ischaemic heart disease events (RR = 1.32; 95% confidence intervals (CI) 1.07, 1.57, p = 0.001) compared with those with values below 46.0%, even after adjustment for age, social class, smoking, body mass index, physical activity, blood cholesterol, lung function (FEV₁), and pre-existing evidence of ischaemic heart disease. Further adjustment for systolic blood pressure reduced the risk slightly (RR = 1.27; 95% CI 1.06, 1.51, p = 0.02) but it remained significant. The relationship was seen in men with and without pre-existing evidence of ischaemic heart disease. The study suggests that an increased haematocrit level plays a part in the development of major ischaemic heart disease events.

(J Epidemiol Community Health 1994;48:112-118)

Patients with polycythaemia rubra vera who have a noticeably raised haematocrit level experience an increased risk of ischaemic heart disease (IHD). This may be a consequence of the influence of haematocrit on blood viscosity. Recent evidence also suggests that the plasma component of viscosity may play a role in the development of atherosclerosis. However, population studies examining the relationship between haematocrit or haemoglobin and major IHD events have been inconclusive. Most studies have reported a positive association between haematocrit or haemoglobin (which are highly correlated) and the risk of heart attacks, and some of these have found the association to be independent of the coronary risk factors. Other studies have found the relationship to be dependent on established cardiovascular risk factors, for example smoking, blood pressure, and blood cholesterol, and others have reported no association. In most of these studies a linear relationship between haematocrit and outcome has been assumed. A recent study, however, has shown a significantly increased risk of heart attacks in subjects with levels above 46.0% compared with those with values below this, independent of the recognised risk factors. This suggests that the relationship may not be linear and that risk may be increased only above certain threshold levels of haematocrit. This study examines the relationship between haematocrit and risk of major IHD events in a prospective study of middle-aged men, and focuses on the role of cardiovascular risk factors in the relationship between ischaemic heart disease and haematocrit.

SUBJECTS AND METHODS
The British Regional Heart Study is a large prospective study of cardiovascular disease comprising 7735 men aged 40–59 years selected from the age-sex registers of one group general practice in each of 24 towns in England, Wales, and Scotland. The criteria for selecting the town, the general practice, and the subjects as well as the methods of data collection, have been reported. Research nurses administered to each man a standard questionnaire that included questions on smoking habits, alcohol intake, physical activity, and medical history. Several physical measurements were made. Classification methods for smoking status, alcohol consumption, occupation (social class), and body mass index (BMI) have been reported. Obesity is defined as a BMI ≥ 28 kg/m², the top 20% of the distribution in these men. The men were asked to indicate their usual pattern of physical activity, under the headings of regular walking or cycling, recreational (weekend) activity, and active physical exercise. A physical activity (exercise) score was derived for each man based on the frequency and type (intensity) of the physical activity. Full details of the derivation of the score have been described. The men were grouped into six broad categories based on their total score: inactive, occasional, light, moderate, moderately vigorous, and vigorous. Those engaged in at least moderate levels of physical activity were classified as active.

HAEMATOCRIT
Blood samples (non-fasting) were taken for measurement of biochemical and haematologi-
ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study
with the risk of major IHD events. There was no consistent association with age or with social class. Smoking, BMI, and obesity were strongly associated with haematocrit (p < 0.0001). Physical activity showed a small but significant inverse relationship (p < 0.0001). Forced expiratory volume in one second (FEV₁) decreased significantly with increasing haematocrit (p < 0.0001).

**HAEMATOCRIT AND PRE-EXISTING DISEASE**

Table 1 also shows the relationship between haematocrit and presence of pre-existing IHD and diabetes. The prevalence of pre-existing IHD and definite myocardial infarction increased significantly with increasing haematocrit. Diabetes was somewhat more prevalent in the lowest haematocrit group but there was no consistent relationship in the other groups.

**Table 1  Haematocrit and coronary risk factors, blood pressure, and blood lipids**

<table>
<thead>
<tr>
<th>Haematocrit</th>
<th>Mean age (y)</th>
<th>Mean manual work (%)</th>
<th>Smoking:</th>
<th>Mean BMI</th>
<th>Mean FEV₁</th>
<th>Pre-existing disease (%)</th>
<th>Mean systolic blood pressure</th>
<th>Mean diastolic blood pressure</th>
<th>Mean cholesterol</th>
<th>Mean triglyceride</th>
<th>Mean HDL cholesterol</th>
<th>Mean glucose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;42 (n=1218)</td>
<td>50.7</td>
<td>63</td>
<td>30</td>
<td>24</td>
<td>30</td>
<td>30</td>
<td>141.4</td>
<td>81.1</td>
<td>6.01</td>
<td>1.52</td>
<td>1.16</td>
<td>5.52</td>
</tr>
<tr>
<td>42-44 (n=1648)</td>
<td>50.0</td>
<td>56</td>
<td>27</td>
<td>24</td>
<td>33</td>
<td>37</td>
<td>145.2</td>
<td>82.5</td>
<td>6.25</td>
<td>1.67</td>
<td>1.17</td>
<td>5.47</td>
</tr>
<tr>
<td>44-46 (n=2018)</td>
<td>50.1</td>
<td>56</td>
<td>24</td>
<td>33</td>
<td>47</td>
<td>39</td>
<td>147.0</td>
<td>82.5</td>
<td>6.42</td>
<td>1.73</td>
<td>1.15</td>
<td>5.47</td>
</tr>
<tr>
<td>46-48 (n=1414)</td>
<td>50.1</td>
<td>57</td>
<td>20</td>
<td>33</td>
<td>47</td>
<td>39</td>
<td>150.0</td>
<td>82.5</td>
<td>6.25</td>
<td>1.82</td>
<td>1.17</td>
<td>5.47</td>
</tr>
<tr>
<td>48+ (n=1048)</td>
<td>50.7</td>
<td>58</td>
<td>14</td>
<td>25</td>
<td>61</td>
<td>39</td>
<td>152.0</td>
<td>84.2</td>
<td>6.42</td>
<td>2.01</td>
<td>1.17</td>
<td>5.52</td>
</tr>
</tbody>
</table>

**Trend, p value**

<table>
<thead>
<tr>
<th>Trend, p value</th>
<th>NS</th>
<th>***</th>
<th>***</th>
<th>**</th>
<th>***</th>
<th>**</th>
<th>NS</th>
<th>NS</th>
<th>NS</th>
<th>NS</th>
<th>NS</th>
<th>NS</th>
</tr>
</thead>
</table>

NS = non-significant; * = p < 0.05; ** = p < 0.01; *** = p < 0.001; BMI = body mass index; FEV₁ = forced expiratory volume in one second.

**IS RAISED HAEMATOCRIT AN INDEPENDENT RISK FACTOR?**

Because of the suggestion that low levels of haematocrit may also be associated with higher risk and that the lowest risk in this study was seen in those with haematocrit levels of 42.0–43.9%, this group has been used as the base group for comparative purposes. The relationship between haematocrit and the risk of a major IHD event was examined adjusting first for age only (table 2, column A) and then, in addition, for age, social class, smoking, physical activity, and BMI (table 2, column B). This latter adjustment reduced the increased risk seen at raised haematocrit values (≥46.0%) but it remained significant. After these adjustments, there was no further increase in risk of major IHD events at higher levels of haematocrit. Additional adjustment for FEV₁, diabetes and presence of IHD (column C) reduced the risk further but a raised haematocrit (≥46.0%) was still associated with a significant increased risk compared with those below 46.0%.

In this study, triglyceride is not an independent risk factor once blood cholesterol has been taken into account. Triglyceride has not therefore been included in the adjustments.

**Figure 1  Major ischaemic heart disease (IHD) event rate/1000/year with 95% confidence interval in relation to the five haematocrit groups.**

**HAEMATOCRIT, BLOOD LIPIDS, AND BLOOD PRESSURE**

Table 1 shows the relationship between haematocrit and systolic and diastolic blood pressure, blood cholesterol, triglyceride, high density lipoprotein (HDL) cholesterol, and blood glucose. There was a strong positive relationship between haematocrit and both systolic and diastolic blood pressure, cholesterol, and triglyceride. No association was seen with HDL cholesterol or with non-fasting blood glucose concentrations. The strong positive association between haematocrit and systolic and diastolic blood pressure, blood cholesterol, and triglyceride persisted after adjustment for age, social class, BMI, and smoking (data not shown).
addition to blood cholesterol. Since blood pressure may be a mediating factor between haematocrit and the risk of a major IHD event, we have further adjusted, first in addition for blood cholesterol (table 2, column D) and then in addition for systolic blood pressure (table 2, column E). Adjustment for blood cholesterol reduced the increased risk of ischaemic heart disease seen in those with raised haematocrit (≥46-0%), but the risk nevertheless increased significantly at levels of 46-0% or above. Adjustment for systolic blood pressure reduced the increased risk of major IHD events even further but a raised haematocrit (≥46-0%) was still associated with a significant increase in risk. Since those with low haematocrit (<42-0%) had the lowest blood pressures and blood cholesterol concentrations, adjustment for these factors increased the risk slightly in these men.

**PRE-EXISTING IHD**

Since the presence of IHD may be associated with an increase in haematocrit levels (table 1) and it has been recognised that haematocrit is raised in patients with IHD,22-24 we have examined the relationship between haematocrit and IHD separately in men with and without pre-existing IHD. Table 3 shows the rate/1000/year and the relative risk of a major IHD event for each of the five haematocrit groups adjusted for age, smoking, social class, physical activity, BMI, lung function (FEV$_1$), and diabetes (column A), in men with and without evidence of pre-existing IHD. In both groups of men, the risk of major IHD increased at levels at and above 46-0%, even after these adjustments – that is, ≥46-0% v the rest.

**POSSIBLE INTERACTIONS**

We have also explored possible interactions between haematocrit, smoking, systolic blood pressure, and blood cholesterol with the risk of IHD. Figure 2 shows the adjusted relative risk of major IHD events in relation to the two haematocrit groups (≥46-0% and <46-0%) plotted on a log scale by smoking, systolic blood pressure, and blood cholesterol concentration. Within all smoking, systolic blood pressure, and blood cholesterol categories, raised haematocrit (≥46-0%) showed higher risk than those with levels below 46-0% (figure 2). The effect was similar at all levels of these risk factors and there was no evidence of an interaction.

**HAEMATOCRIT AND SERUM PROTEIN**

It is well established that haematocrit is an important determinant of blood viscosity. Since circulatory protein is also a major determinant of blood viscosity, we examined whether total serum protein is related to haem-

### Table 2 Haematocrit and adjusted relative risk (RR) (95% confidence interval) of major ischaemic heart disease (IHD) events

<table>
<thead>
<tr>
<th>Haematocrit level</th>
<th>No of men</th>
<th>No of IHD cases</th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;42</td>
<td>1218</td>
<td>82</td>
<td>1-06</td>
<td>1-06 (0-79,1-43)</td>
<td>1-01 (0-73,1-39)</td>
<td>1-07 (0-68,1-48)</td>
<td>1-09 (0-79,1-49)</td>
</tr>
<tr>
<td>42-</td>
<td>1648</td>
<td>100</td>
<td>1-00</td>
<td>1-00</td>
<td>p&lt;0.0001</td>
<td>p&lt;0.0001</td>
<td>1-00</td>
</tr>
<tr>
<td>44-</td>
<td>2018</td>
<td>139</td>
<td>1-15</td>
<td>1-08 (0-84,1-40)</td>
<td>1-00 (0-76,1-32)</td>
<td>0-97 (0-74,1-30)</td>
<td>0-95 (0-72,1-39)</td>
</tr>
<tr>
<td>46-</td>
<td>1414</td>
<td>140</td>
<td>1-75</td>
<td>1-55 (1-17,2-05)</td>
<td>1-42 (1-06,1-90)</td>
<td>1-36 (1-05,1-80)</td>
<td>1-31 (1-06,1-73)</td>
</tr>
<tr>
<td>48-</td>
<td>1048</td>
<td>119</td>
<td>1-92</td>
<td>1-55 (1-17,2-05)</td>
<td>1-35 (1-01,1-82)</td>
<td>1-25 (0-93,1-68)</td>
<td>1-17 (0-87,1-58)</td>
</tr>
<tr>
<td>Relative risk ≥46-0% v rest</td>
<td>1-70</td>
<td>1-48 (1-23,1-77)</td>
<td>1-40 (1-17,1-67)</td>
<td>1-32 (1-10,1-57)</td>
<td>1-27 (1-06,1-51)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(A) Adjusted for age, smoking, social class, BMI, lung function, and diabetes.
(B) Adjusted in addition for blood cholesterol.

### Table 3 Haematocrit and adjusted relative risk (RR) (95% confidence interval) of major ischaemic heart disease (IHD) events in men with and without pre-existing IHD

<table>
<thead>
<tr>
<th>Haematocrit level</th>
<th>No evidence of IHD</th>
<th>Pre-existing evidence of IHD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate/1000/year</td>
<td>RR A</td>
</tr>
<tr>
<td>&lt;42</td>
<td>922</td>
<td>50 (44)</td>
</tr>
<tr>
<td>42-</td>
<td>1252</td>
<td>4-7 (58)</td>
</tr>
<tr>
<td>44-</td>
<td>1528</td>
<td>4-9 (71)</td>
</tr>
<tr>
<td>46-</td>
<td>1303</td>
<td>8-2 (80)</td>
</tr>
<tr>
<td>48-</td>
<td>723</td>
<td>7-6 (52)</td>
</tr>
<tr>
<td>Relative risk ≥46-0% v rest</td>
<td>p=0.0001</td>
<td>p=0.002</td>
</tr>
</tbody>
</table>

(A) Adjusted for age, smoking, social class, BMI, lung function, and diabetes.
(B) Adjusted in addition for blood cholesterol.

(C) Adjusted in addition for blood systolic pressure.
Figure 2. Raised haematocrit (≥46%) and adjusted relative risk of major ischaemic heart disease (IHD) events in relation to smoking, systolic blood pressure, and blood cholesterol. Adjusted for age, social class, smoking, physical activity, body mass index, lung function, pre-existing IHD, diabetes and each of the other factors.

Discussion
In this study of middle-aged British men, a raised haematocrit (≥46) was associated with an increase in risk of major IHD events independent of age, social class, body weight, physical activity, lung function, and pre-existing IHD. Although most studies have found a positive association between haematocrit and risk of heart attacks, many have found the relationship to be dependent on established coronary risk factors in particular blood pressure and blood cholesterol. In this study haematocrit showed a strong positive association with both blood cholesterol and blood pressure. The positive association between haematocrit and blood pressure is well documented and it is thought that a raised haematocrit predisposes to hypertension. If raised haematocrit does indeed produce a rise in blood pressure, then adjusting for blood pressure may not be appropriate, except to assess whether the relationship is mediated through blood pressure. Several studies have also noted a strong positive association between blood cholesterol and haematocrit and it is suggested that the association may be due to changes in plasma volume resulting in both a rise in blood cholesterol and in haematocrit levels. It has also been reported that cholesterol and triglycerides cause rigidification of erythrocytes because of metabolic relations between lipoprotein fractions and cell membrane, and this is likely to result in increased haematocrit. In the present study the positive relationship between haematocrit and major IHD events was reduced after adjusting for blood cholesterol in addition, but the relationship remained significant. Further adjustment for systolic blood pressure reduced the excess risk further but the risk still increased at levels of 46% or above. It is well established that the presence of IHD is associated with increased haematocrit levels. However, the positive relationship between haematocrit and the risk of heart attacks was seen in the present study even after exclusion of men with evidence of IHD. Indeed the relationship was similar in both men with and without IHD in that haematocrit levels ≥46% were associated with about a 30% increase in risk in both groups.

It is of some interest that the most noticeable effects of adjustments for blood cholesterol and for systolic blood pressure were seen at the highest levels of haematocrit (≥48%). Although some of the excess risk was due to raised systolic blood pressure, this did not account for all the excess risk seen. This implies that the mechanism in the haematocrit-IHD relationship is either to some extent independent of blood lipids and blood pressure or that the process of adjustment does not take into account the imprecision of the measured risk factors.

Other Studies
Several studies have found the relationship between haematocrit and heart attacks to be dependent on blood cholesterol and systolic blood pressure. In these studies, a linear relationship has been assumed and multiple regression analyses have been used, fitting haematocrit as a continuous variable and assessing the significance of the trend after adjustment. In the present study, haematocrit was raised only at levels of 46% and beyond with no further increase at higher levels after adjustment for the established coronary risk factors. Furthermore, men with low haematocrit had a slight increase in risk after adjustment for cholesterol and blood pressure compared with those within the range 42−0−45%. In one study, those with a low haematocrit have been shown to have a slight increase in risk of coronary heart disease mortality, so that assuming a linear relationship would flatten the trend, even though the risk might be significantly raised at higher levels of haematocrit. Nevertheless, the Puerto Rican Study found a significant positive association between haematocrit (fitted as a continuous variable) and risk of heart attacks even after adjustment for the established risk factors, and in the Stockholm Prospective Study, haemoglobin, which is highly correlated with haematocrit, was found to be significantly and independently associated with risk of myocardial infarction. A recent study which has used cut-off points has found a significant relationship between a raised haematocrit (≥46%) and the risk of heart attacks even after adjustment for the coronary risk factors. Raised haematocrit was associated with a twofold increase in the risk of heart attacks compared with those.
with lower levels. The positive association between a raised haematocrit and IHD has also been observed in women. In a study of 1438 women aged 45–74, a haematocrit level over 45.0% was associated with an increased risk of IHD mortality even after adjustment for smoking. No data were available on blood cholesterol or blood pressure.9

**BLOOD VISCOSITY**

Although the mechanism for the role of haematocrit in the development of atherosclerosis is uncertain, there is growing speculation that its effect may be via blood viscosity.4,10 Haematocrit is the strongest determinant of whole blood viscosity. A linear increase in haematocrit produces an exponential increase in blood viscosity, thereby reducing blood flow particularly at sites of vascular damage and low shear rate. The exponential nature of this association may provide an explanation for the non-linear shape of the relationship between haematocrit and IHD events. The adverse effect of raised haematocrit (≥46%) within the normal reference range, as within the polycythemic range, may be mediated via a viscosity induced reduction in blood flow.

Plasma viscosity, although less important as a determinant of whole blood viscosity than haematocrit,2 may also make an important contribution to cardiovascular risk. Fibrinogen is an important determinant of plasma viscosity, particularly at low shear rates, and is an independent predictor of cardiovascular events.31 Cigarette smoking is the major environmental determinant of the fibrinogen level and about half of the IHD risk in cigarette smokers can be attributed to their higher fibrinogen level.12 It is also suggested that fibrinogen variations within the levels encountered in the general population may reflect the activity and instability of the atherosclerotic plaque.33 However, a recent report from the Caerphilly study suggests that plasma viscosity has an influence on IHD risk which is independent from that of fibrinogen, although the conclusion is dependent on the precise adjustment used.4 Fibrinogen was not measured in this study and thus the independent contributions of haematocrit, plasma viscosity, and fibrinogen concentration to the IHD risk need to be examined further in longitudinal studies with data on all these factors.

**CONCLUSION**

This study suggests that a raised haematocrit plays a role in the development of major IHD. There was no difference in the risk of IHD at haematocrit levels within the range 42.0–45.9% observed in population studies. At levels of 46.0% and beyond the risk of heart attacks increased. Some of the increased risk of IHD was associated with the established coronary risk factors but even after adjusting for these risk factors there still remained an independent effect of a raised haematocrit on the risk of major IHD events. This effect could be related to the impersistence with which the adjusted variables are measured, or it could be truly independent. The findings support the suggestion that blood rheology, of which the haematocrit is an important component, plays a part in the development of IHD.

The British Regional Heart Study is a British Heart Foundation Community Group and is also supported by the Department of Health and The Stroke Association. Haematocrit measurements were determined in the Department of Haematology, Queen Elizabeth Hospital, Birmingham, supported by the Department of Health. We thank Professor I Stuart for his valuable comments on the paper.